PPT-Pharmacokinetic Parameters & Drug Handling in Continuous Renal Replacement Therapy

PCRRT London 18 th July 2015 Marie O Meara Pharmacist Honorary Clinical Lecturer Kings College London Disclosures I am currently an employee of Abbvie Ltd the opinions expressed throughout this presentation are my own. Excretion of . Aristolochic. Acid I in . the IPK . Page . 1. Mariana Babayeva MD, PhD. Touro College of Pharmacy,. New York, NY, USA. Aristolochic. Acid I. Page . 2. Compound extracted from plant . “ Any extracorporeal blood purification therapy intended to substitute for impaired renal function over an extended period of time and applied for or aimed at being applied for 24 hours /day.” . Patrick D Brophy, MD, MHCDS. Director Pediatric Nephrology. Professor. The University of Iowa. London 2015. Many questions remain . unanswered . What therapy should we use?. When should we start it?. LA GESTIONE INFERMIERISTICA DEL PAZIENTE CON IRA IN TERAPIA INTENSIVA. Silvi Marina, 24-26 Maggio 2013. Giovanni . Biccari. DIPARTIMENTO NEFROLOGIA E UROLOGIA – UOS COORDINAMENTO SERVIZIO EMODIALISI. Geriatric Patients. Disproportionately high prescription drug use exists in the elderly.. 12% of Americans are age 65 years or older.. This 12% consumes 31% of prescribed drugs.. Geriatric patients experience more adverse drug reactions and drug-drug interactions than younger patients do.. Learning Objectives. Describe treatment options for renal replacement . therapy to improve awareness and understanding.. Use evidence-based strategies to . manage patients with kidney failure in need of renal replacement therapy to improve outcomes. . CRRT BackgroundWhena patient is initiated on CRRT antimicrobial therapy often requires adjustment to ensure adequate drug concentrations are achievedCVVHDremoves solutes including drugs via diffusion Patient back to baseline. Vitals stable. . Sent to OSH where CT head shows old stroke.. Work up at outside including cardiac echo, carotid US negative.. PMH: as above plus two previous episodes of falling. Therapeutic Drug . Monitoring. Background and historical introduction . Until the 1960s, . trial and error . was the most common scenario for drug management. . Even though the . guiding principles . ICH Topic E 7 Studies in Support of Special Populations: Geriatrics Step 5NOTE FOR GUIDANCE ON STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS (CPMP/ICH/379/95) APPROVAL BY CPMP September 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF THE PHARMACOKINETICS OF MEDICINAL PRODUCTS IN PATIENTS WITH IMPAIRED HEPATIC DISCUSSION IN THE EFFICACY WORKIN Acute kidney injury. Definition of AKI. AKI is defined as any of the following . Increase in . SCr. by >0.3mg/dl (>26.5lmol/l) within 48 hours; . or Increase in . SCr. to >1.5 times baseline, which is known or presumed to have occurred within the prior 7 days;. Al-. Zahraa. Medical College and Scientific Research. Block: . Metabolic block. Lecture: . Renal replacement therapy. Lecturer: . Supportive Therapies. Jordan M. Symons. University of Washington School of Medicine. Seattle Children’s Hospital. Stage-Based Management of AKI. Kidney Intl Supplements (2012) 2: 19-36. Natural History of Acute Kidney Injury (AKI).